FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

	OMB APPRO	OVAL
	OMB Number:	3235-0287
	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,				' '										
1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol TG THERAPEUTICS, INC. [TGTX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
WEISS MICHAEL S				1	TO THE IOTICS, INC. [IGIA]									X Director			10% Owner		wner		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)								1	X	Office	cer (give title Other (s w) below)				
2 GANSEVOORT STREET, 9TH FLOOR					06/	06/13/2019									CEO and President						
(Street) NEW YORK NY 10014				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
(City)	(St	ate) (Zip)														orm filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4)			A) or , 4 and	and 5) Securi Benefi Owned		ties cially I Following	Form:	nership Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
									Code	v	Amount (A) or (D)		(A) or (D)	Price	, ı	Reported Transaction(s) (Instr. 3 and 4)				(111511.4)	
COMMON STOCK 06/13/20					2019				A	A 1,179,380 ⁽¹⁾ A		\$	0	12,828,185(2)			I	See Note 3 ⁽³⁾			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deel Execution if any (Month/I	on Date,	4. Transaction Code (Instr. 8)				6. Date Exercisal Expiration Date (Month/Day/Year)		e Amo Secu Unde Deriv Secu		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price Deriva Secur (Instr.	rative crity S	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ov Fo Dir or (I)	vnership orm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Nun of	ount nber res							

Explanation of Responses:

- 1. Reflects an annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provides the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is \$100 million greater than the Market Capitalization on the date of grant, but in no event before January 1, 2021.
- 2. Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.
- 3. The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member.

<u>/s/ Michael Weiss</u> <u>06/14/2019</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.